Dr. Chacko was most recently CFO of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche in February 2018. At Ignyta, he had a broad operational role and helped raise over $500 million in capital. During his tenure, the company grew from fewer than 20 employees and a $50 million enterprise value to 125 employees and a $1.7 billion enterprise value at the time of acquisition. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital, where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company.
Dr. Chacko currently serves on the board of directors of 4D Molecular Therapeutics (Nasdaq: FDMT) and chairs the Western Regional Selection Committee for the Marshall Scholarship. He previously served on the board of directors of Turning Point Therapeutics (Nasdaq: TPTX), Bonti (acquired by Allergan), EnvisionRx (acquired by Rite Aid), RentPath, and the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford; and he was a board observer to Par Pharmaceutical (acquired by Endo), IMS Health and Quintiles Transnational.
Dr. Chacko concurrently received his MD with AOA honors from UCLA and his MBA with Distinction from Harvard Business School. He also received a MSc from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the University Valedictorian.
What is Jacob Chacko's net worth?
The estimated net worth of Jacob Chacko is at least $161,105.36 as of September 13th, 2021. Dr. Chacko owns 6,388 shares of ORIC Pharmaceuticals stock worth more than $161,105 as of September 18th. This net worth estimate does not reflect any other investments that Dr. Chacko may own. Additionally, Dr. Chacko receives a salary of $790,960.00 as CEO at ORIC Pharmaceuticals. Learn More.
How old is Jacob Chacko?
Dr. Chacko is currently 42 years old. There are 7 older executives and no younger executives at ORIC Pharmaceuticals. Learn More.
What is Jacob Chacko's salary?
As the CEO of ORIC Pharmaceuticals, Inc., Dr. Chacko earned a total compensation package of $5,873,786.00 in 2020. Dr. Chacko earned a salary of $489,167.00, options awards of $5,082,831.00, non-equity compensation of $300,800.00, and other compensation of $988.00.
How do I contact Jacob Chacko?
The corporate mailing address for Dr. Chacko and other ORIC Pharmaceuticals executives is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. ORIC Pharmaceuticals can also be reached via phone at 650-388-5600 and via email at [email protected]
Has Jacob Chacko been buying or selling shares of ORIC Pharmaceuticals?
During the last ninety days, Jacob Chacko has sold $387,673.00 in shares of ORIC Pharmaceuticals stock. Most recently, Jacob Chacko sold 3,736 shares of the business's stock in a transaction on Wednesday, September 15th. The shares were sold at an average price of $25.06, for a transaction totalling $93,624.16.
Who are ORIC Pharmaceuticals' active insiders?
Are insiders buying or selling shares of ORIC Pharmaceuticals?
During the last twelve months, insiders at the sold shares 29 times. They sold a total of 358,079 shares worth mmore than $9,735,825.86. The most recent insider tranaction occured on September, 15th when Jacob Chacko CEO bought 3,736 shares worth more than $93,624.16. Insiders at ORIC Pharmaceuticals own 24.6 % of the company.
Information on this page was last updated on 9/15/2021.